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Abstract
A National Institutes of Health (NIH) workshop was convened in Bethesda, MD on September 26–27, 2011, with
representative scientific leaders in the field of proteomics and its applications to clinical settings. The main purpose
of this workshop was to articulate ways in which the biomedical research community can capitalize on recent
technology advances and synergize with ongoing efforts to advance the field of human proteomics. This executive
summary and the following full report describe the main discussions and outcomes of the workshop.
Executive summary
A National Institutes of Health (NIH) workshop was
convened in Bethesda, MD on September 26–27, 2011,
with representative scientific leaders in the field of pro-
teomics and its applications to clinical settings. The main
purpose of this workshop was to articulate ways in which
the biomedical research community can capitalize on re-
cent technology advances and synergize with ongoing
efforts to advance the field of human proteomics.
Proteins are the major components of biological net-
works and molecular machines, and proteins are the tar-
gets for the large majority of drugs available today.
Participants in this Workshop recognized that a deeper
knowledge of the human proteome could help fill the
gap between genomes and phenotypes, transform the
way we develop diagnostics and therapeutics, and
thereby enhance overall biomedical research and future
healthcare. The Human Genome Project and its many
follow-on initiatives, including the HapMap and
ENCODE, together with advances in protein sciences,
have provided a foundation for proteomic technologies
and informatics resources. Several major initiatives are
already moving toward deep characterization of the
human proteome, including the antibody-based Human
Protein Atlas, the NIH Common Fund Protein Capture
Reagents, the mass spectrometry-based Peptide Atlas
and Selected Reaction Monitoring (SRM) Atlas, and the
Human Proteome Project organized by the Human
Proteome Organization. Several leading laboratories
have demonstrated that about 10,000 protein products,
of the about 20,000 protein-coding human genes, can
be identified and quantified in a single experimental
specimen; this figure may represent nearly the complete
complement of proteins actually expressed in a single
cell type. In yeast the complete expressed proteome has
been identified. Even though a more comprehensive
characterization of the dynamic aspect of the proteome
will require further technology development, it is a dis-
ruptive concept that almost all of the primary products
of the genome can be detected at the protein level in
one single experiment.
The Workshop was organized in five sessions: (1) pro-
tein networks; (2) integrating proteomics with other
omics; (3) quantitative proteomics by exploratory and
targeted methodologies; (4) study design and statistical
challenges in clinical proteomics; and (5) proteomic
technologies in a clinical setting. Sessions 1–3 consti-
tuted a main theme on systems biology; sessions 4–5
represent a theme on strategies for clinical proteomics.
The full agenda is at http://www3.niddk.nih.gov/fund/
other/HumanProteome2011. This executive summary
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http://www.clinicalproteomicsjournal.com/content/9/1/6and the following full report describe the main discus-
sions and outcomes of the workshop.
Protein networks: toward a comprehensive wiring
diagram of human cells
The interactome network of cells is the complete set of
macromolecular interactions that take place between
genes and gene products; it is mostly mediated by pro-
teins. Pull-down of diverse protein complexes and se-
quencing of the components, plus other direct
measurements of protein-protein, protein-nucleic acid,
and protein–lipids interactions now make it feasible to
create wiring diagrams for systems biology. The capabil-
ity of quantifying the main gene products and providing
information on post-translational modifications and
splice variants of proteins addresses the dynamic nature
of the networks. Experimental and natural perturbations
of cultured cells and of whole organisms can then reveal
connectivity and can test hypotheses of the blueprint
and dynamic regulation of phenotypes. Informatics tools
such as Cytoscape and databases such as BioGRID pro-
vide means of visualizing pathways, networks, and
interactomes.
Integrating proteomics with other omics
Detailed integration of data and knowledge from mul-
tiple omics technology platforms is essential for building
and understanding the pathways from genome to pheno-
types and the influence of environmental and behavioral
variables. The influence of allelic variants, splice variants,
and post-translational modifications must be assessed in
combined analyses of mRNA and protein abundance and
response to perturbations. Single nucleotide polymorph-
isms and alternative splicing can influence sites of post-
translational modifications, magnifying their downstream
effects. Linking gene expression, protein expression, and
metabolomics has become an attractive approach, facili-
tated by new bioinformatics tools.
Quantitative proteomics by exploratory and targeted
mass spectrometry methods
There has been stunning progress in mass spectrom-
etry-based proteomics, with new technologies and com-
binations of instrumentation for bottom-up peptide
analysis, top-down protein analysis, and targeted quanti-
tative analysis of proteotypic peptides of selected pro-
teins. The equipment and reagent sector for proteomics
is a major economic engine. These advances enable
much more potent approaches for biomarker develop-
ment and protein targeting with therapeutic agents. In
contrast to recent studies limited to the most abundant
dozens or hundreds of proteins in a biological speci-
men, current experiments are identifying, with a false
discovery rate of one percent, and quantifying
approximately 10,000 proteins from different genes in
human cell lines, for example. Such deep analyses per-
mit direct comparison with deep sequencing of the
transcriptome, as well as with protein expression based
on immunohistochemistry, as documented in the
Human Protein Atlas.
Study design and statistical challenges in clinical
proteomics
For the past decade, many of the individual institutes of
the NIH have supported programs and projects to gen-
erate potential protein biomarkers for early or more
specific diagnosis or prognosis of a wide array of dis-
eases. There are many complex challenges in developing
such omics-based tests. Heterogeneity of etiology,
pathogenesis, and responses to therapy among patients
with identical diagnoses, is common. Knowledge of
mechanisms, mediated by pathways and networks, is
fundamental to moving beyond statistical correlation as
a basis for biomarker development. Integration of data
across multiple levels of omics analyses should facilitate
such knowledge development. Several general recom-
mendations for biomarker discovery projects were also
made during the discussion. Participants emphasized
the importance of specifying as early as possible in the
process the intended clinical use, and the importance of
proper study design in order to avoid introducing bias.
Finally, it is important for translational scientists to
understand the long path of discovery, confirmation,
validation, clinical trials, and FDA approval to establish
test validity and utility and gain reimbursement of the
laboratory service.
Proteomic technologies in a clinical setting
The late-stage translation of proteomic technologies and
protein biomarker candidates into clinical tests requires
specification of the intended clinical use, sufficient evi-
dence in preliminary studies to support the investment
for a large-scale validation trial, demonstration of reliable
test performance characteristics, and sufficient clinical
benefit to gain acceptance by the clinical community. It
is counterproductive to try to short-circuit these com-
plex steps, especially in the absence of a strong biological
foundation for the biomarker candidate or panel of bio-
markers. The development of a roadmap for the transla-
tion of proteomics technologies into clinical settings will
require close collaboration between researchers, indus-
tries, regulators, clinical chemists and clinicians, includ-
ing private-public partnerships to leverage existing NIH
programs. Such a partnership would accelerate the devel-
opment of clinically useful technologies and biomarkers
and make a significant impact to fulfill the unmet clinical
needs for patients’ personalized health care.
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Human proteome networks in health and disease - A
major scientific opportunity
A session within the Workshop was dedicated to discus-
sion of potential scientific opportunities and identification
of the most compelling ideas for future developments in
the field of proteomics. Several potential concepts were
considered in the context of the presentations that were
made by the speakers. The participants reached consensus
that a special opportunity exists at this time for utilizing
modern proteomics to link data from multiple levels of
omics technologies and build wiring diagrams of human
cells and tissues through interactome networks and related
phenomena. The focus on protein interactome networks
would be salient for all disease processes and would yield a
stronger foundation for the many NIH institute-specific
programs seeking a more effective translation to biomarker
development.
Full report of the NIH workshop on the human
proteome
A National Institutes of Health (NIH) workshop was
convened in Bethesda MD on September, 26–27, 2011
with representative scientific leaders in the field of pro-
teomics and its applications to clinical settings. The main
purpose of this workshop was to articulate ways in which
the biomedical research community can capitalize on re-
cent technology advances and synergize with ongoing
efforts to advance the field of human proteomics.
Proteins are the major components of biological net-
works and molecular machines, and proteins are the tar-
gets for the large majority of drugs available today.
Participants in this Workshop recognized that a deeper
knowledge of the human proteome could help fill the
gap between genomes and phenotypes, transform the
way we develop diagnostics and therapeutics, and
thereby enhance overall biomedical research and future
healthcare. The Human Genome Project and its many
follow-on initiatives, including the HapMap and
ENCODE, together with advances in protein sciences,
have provided a foundation for proteomic technologies
and informatics resources. Several major initiatives are
already moving toward deep characterization of the
human proteome, including the antibody-based Human
Protein Atlas, the mass spectrometry-based Peptide Atlas
and Selected Reaction Monitoring (SRM) Atlas, and the
Human Proteome Project organized by the Human
Proteome Organization [1-4]. Leading laboratories have
demonstrated that protein products of up to ~10,000 of
the ~20,000 protein-coding human genes can be identi-
fied and quantified in a single experimental specimen
[5-7]; this figure may represent nearly the complete
complement of proteins actually expressed in a single
cell type. In yeast the complete set of expressed proteins
has been identified. It is a disruptive concept that the
proteome can now be analyzed comprehensively and
that all of the primary protein products of the genome
can be detected.
The Workshop was organized in five sessions: (1) pro-
tein networks; (2) integrating proteomics with other
omics; (3) quantitative proteomics by exploratory and tar-
geted methodologies; (4) study design and statistical chal-
lenges in clinical proteomics; and (5) proteomic
technologies in a clinical setting. Sessions 1–3 constituted
a main theme on systems biology; sessions 4–5 represent
a theme on strategies for clinical proteomics. The full
agenda is at http://www3.niddk.nih.gov/fund/other/
HumanProteome2011. The following report describes the
main discussions and outcomes of the workshop.
Protein networks: Toward a comprehensive wiring
diagram of human cells (Marc Vidal, Dana-Farber Cancer
Institute, chair)
Understanding the detailed mechanistic paths between
genotypes and phenotypes is one of the most important
goals of biology, and critical in the quest for new thera-
peutics. Complex genotype-to-phenotype relationships
exist in common disorders and traits, but even Mendel-
ian disorders are complicated by phenomena such as in-
complete penetrance, variable expressivity, pleiotropy
and modifier genes. Recent advances in genome biology
have revealed extremely complex links between geno-
typic modifications and phenotypic changes in cancers,
for example. No single phenotype will be fully explained
by simple changes in any single gene, because gene/en-
vironment interactions and perturbations of biological
systems and cellular networks, not single proteins,
underlie genotype-phenotype relationships [8]. Vidal
defined the “interactome network” of cells as the
complete set of macromolecular interactions that can
take place between genes and gene products, including
protein-protein, protein-DNA, protein-RNA, DNA-DNA,
RNA-RNA, enzyme-substrate and post-translational
modification interactions. Maps of such macromolecular
interactions generated at the scale of the whole proteome
will be necessary, although still not sufficient, to fully
understand biological complexity. He characterized the
current state-of-the-art on interactome networks as
similar to the exciting time of the late 1990s for the
Human Genome Project. He concluded that the com-
munity is ready to produce a “systematic, unbiased,
freely available wiring diagram for systems biology” on
which to add logical and dynamic relationships. Proteo-
mics is needed to inform those relationships.
Suzanne Gaudet, Dana-Farber Cancer Institute, pre-
sented “Predicting phenotypes: quantities and dynamics
in proteomics”. Because of complex systems properties
that underlie most biological processes, identical
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comes. In her example, HeLa cells, when treated with
the apoptosis-inducing ligand TRAIL, produce two strik-
ingly different populations of cells: 80% die and the
remaining 20% survive [9]. Cells that survive this treat-
ment are capable of generating the same bi-modal re-
sponse when treated a second time. She demonstrated
how this variability is mediated biochemically; computer-
generated, model-based simulations were able to recap-
itulate this behavior. In the case of apoptosis, appropriate
measurements for a dozen proteins accurately predict the
phenotypic outcome of such cell perturbations [10]. Bio-
logical experiments over many years and from many la-
boratories have led to a predictive wiring diagram of this
specific biological process. For more general proteome-
scale wiring diagram maps, three major components are
needed: i) network information on binding partners and
biochemical reactions; ii) quantitative information on
protein levels, protein affinities and reaction rates; and iii)
biosensors to measure response dynamics in situ.
Kara Dolinski, Princeton University, presented “System-
atic knowledge capture and representation: the Biological
General Repository for Interaction Datasets (BioGRID)”
[11]. She and her colleagues are tackling the challenge of
generating cellular wiring diagrams by collecting and cur-
ating published information on macromolecular interac-
tions from both small-scale bottom-up approaches and
large-scale proteome-wide mapping enterprises. She pre-
sented numbers of downloads and volume of traffic on the
BioGrid website that summarizes information so far for
yeast and for human biology. Dolinski highlighted exciting
prospects for visualization of interactome networks
derived from curating literature to generate Bayesian mod-
els of disease-specific networks. BioGrid and other data-
bases have become critical for further development of
interactome network model-based systems biology. Data-
bases such as the ProteomeXchange, that have emerged as
a point of connection for the mass spectrometric prote-
omic data repositories, should play a key role in the devel-
opment of a comprehensive wiring diagram of human
cells. However, a broad strategy for sustained support of
key data resources is needed.
Integrating proteomics with other omics (Mark Gerstein,
Yale University, chair)
Given the scale of other datasets, particularly those
derived from next-generation sequencing, much added
value is achieved from integrating proteomics datasets
with other data. Four key themes for such data integra-
tion were identified.
a) “Direct Integration of mRNA Gene Expression and
Protein Abundance Datasets”. Gerstein described two
forms: first, a simplified context for the past decade
comparing levels of mRNAs and their corresponding
proteins and changes in those levels after a
perturbation in a time-course experiment or with
successive measurements of clinical specimens; and,
second, a more elaborate future context in relation
to allelic expression, comparing maternal and
paternal alleles both for gene expression and protein
abundance using the exact sequences that come
from mass spectrometry or transcriptome
sequencing [12-14]. The "future case” allows for the
examination in detail of the effects of specific
mutations on gene expression, using the maternal
and paternal alleles as perfectly matched controls.
For quantitative proteomics, both for the simpler
case of comparing molecular concentrations and the
allelic case, one would need the protein abundance
sets, preferably including post-translational
modifications and splice variants, precisely matched
against RNA-Seq sets.
b) “Connecting Proteomics Data to the Huge Amount of
Variation Data”. Joel Bader, Johns Hopkins
University, addressed the idea of connecting
proteome data, particularly in the form of networks,
with the huge amount of variation data coming from
personal genomic sequencing. Other participants
also emphasized the importance of connecting the
complex aspects of proteins to the variation data. In
particular, a single nucleotide polymorphism (SNP)
can differentially affect different transcripts from the
same gene. Moreover, SNPs potentially can have
stronger effects than one might imagine by hitting a
splice site or a site of post-translational modification
in proteins; e.g. a splice SNP could result in removal
of an entire exon. These features could be addressed
by developing large datasets of protein isoforms and
linking these against gene annotations [15,16].
c) “Multi-dimensional Data Integration”. All speakers
and participants emphasized that proteomics data
should be integrated with diverse biomedical
information. Robert Gerszten, Massachusetts
General Hospital, discussed the importance of
connecting proteomics data with clinical
measurements and metabolomics, and Gerstein
emphasized the usefulness of connecting the protein
networks with three-dimensional structures of
proteins and protein complexes. This integration
opportunity could be further pursued by solving co-
crystal structures of proteins and using these to
provide molecular details for interaction networks.
Gil Omenn, University of Michigan, extended this
comment by citing current work using I-TASSER
algorithms to predict three-dimensional structures
and conformations of pairs of splice variant proteins
differentially expressed in Her2/neu breast cancer
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sequence differences between the splice variants
[17].
d) “The Complexities and Subtleties of Detailed
Integration”. The challenges in achieving data
integration in the framework of a working database
system were underscored by Rolf Apweiler, European
Bioinformatics Institute [18]. He pointed out that, in
many instances, while one can get most of the
integration done, there are some unresolved cases,
including such major aims as connecting the
genomics data from Ensembl to the proteomics
information in Uniprot. Zhiping Weng, University of
Massachusetts Medical School, highlighted how
chromatin marks might be used to predict gene
expression information in the framework of an
integrative model. This approach represents moving
beyond simply putting together the datasets to
actually exploring how one dataset might be used to
predict another.
Quantitative proteomics by exploratory and targeted
mass spectrometry methodologies (Matthias Mann, Max
Planck Institute of Biochemistry, chair)
The four speakers (Matthias Mann; Joshua Coon, Univer-
sity of Wisconsin-Madison; Robert Moritz, Institute for
Systems Biology; Forest White, Massachusetts Institute of
Technology) addressed a mixture of technological, data-
centric and functional biological proposals and issues.
They emphasized the stunning technological progress in
mass spectrometry-based proteomics [5-7,19-21]. Large-
scale analyses corresponding to in-depth microarray and
RNA-Seq methods for gene expression are now feasible.
Since proteins are the workhorses of the cell, the capabil-
ities of MS-based proteomics are crucially important to
obtain a balanced view of the cell and to put genetic and
genomic findings in biological context.
“Expression Proteomics”. Mann and Coon described re-
cent and emerging innovations in shotgun proteomics.
In contrast to studies limited to the most abundant doz-
ens or hundreds of proteins in a specimen, the proteome
can now readily be analyzed in great depth and with high
quantitative accuracy. In yeast, nearly complete coverage
of the expressed genes has already been achieved. Mann
presented data obtained using the Orbitrap-Elite plat-
form where more than 10,000 proteins were identified in
a single lysate from a human HeLa cancer cell line [7]
and from 10 other human cell lines, representing a broad
range of organs of origin. Ruedi Aebersold’s laboratory
has published similar deep quantitation of U20S osteo-
sarcoma cells [6]. Comparison to deep sequencing
(RNA-seq) data suggests that the majority of the func-
tionally active proteome can already be quantified with
such new technology [5-7]. However, to extend these
capabilities to protein isoforms and to make them ac-
cessible to more laboratories, vigorous technology de-
velopment should be pursued, using combinations of
mass spectrometry methods and bioinformatics tools
that detect post-translational modifications. Mann also
presented a framework for intelligent data acquisition
and real-time database searching using MaxQuant-Real
Time, permitting searches according to specific GO
terms (the example of the kinases activities was illu-
strated) and finding specific kinds of peptide modifica-
tions [22]. This capability is necessary for obtaining
greater sequence coverage of the individual proteins,
which would be helpful in distinguishing and mapping
protein isoforms. Coon also described a smart data ac-
quisition strategy in which the mass spectrometer is
directed to identify specific peptides. Such strategies
help to increase proteome coverage in shotgun experi-
ments because they allow including important peptides
for sequencing and excluding irrelevant ones. For pro-
teins up to 50,000 molecular weight, top-down meth-
ods are becoming very useful [21]. Using this approach
3,000 different molecular species, representing about
1,000 main gene products, can be fully characterized
by mass spectrometry in a single project. The applica-
tion and further development of these approaches
should be encouraged.
“Targeted proteomics with selected reaction monitoring
(SRM)”. Robert Moritz described the SRM Atlas, a
wholeproteome initiative jointly led by the Aebersold la-
boratory at ETH-Zurich and the Moritz laboratory at the
Institute for Systems Biology in Seattle using the Triple-
Quad mass spectrometers rapidly emerging from mul-
tiple manufacturers. In Selected Reaction Monitoring,
several proteotypic peptides distinctive for each targeted
protein are chosen for their expected transition proper-
ties in the mass spectrometer and then identified and
quantified using corresponding heavy-labeled spiked-in
peptides. Within just 2–3 years, multiple peptides for
each of the expressed yeast genes and now 99% of the
20,300 human gene-coded proteins have been prepared;
their mass spectra have been determined and shared
publicly through the SRM Atlas. Proteins that are bio-
marker candidates from discovery phase research can be
assayed with SRM peptides to facilitate experimental and
clinical studies across a wide array of diseases. These
peptide and spectra resources are valuable assets for the
entire proteomics and life sciences research communi-
ties. This database of SRM peptide transitions can also be
used as a reference to interpret experiments in which all
peptides in a particular mass range are fragmented together.
Measuring many of these proteins in complex specimens
like tissue lysates or plasma will require further increases in
sensitivity, using either anti-peptide antibodies [23] or
enhanced mass spectrometry.
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tative and targeted expression proteomics, an area of
great promise is the large-scale identification, quantifica-
tion, and mapping of post-translational modifications.
Tens of thousands of phosphorylation, ubiquitinylation,
acetylation, and glycosylation sites have been uncovered
by mass spectrometry. Forrest White pointed out that we
should now focus on the biological functions of these
modifications, truly a grand challenge. Particular direc-
tions can include the mapping of kinase/substrate rela-
tionships using modified kinases, starting with specific
pathways of particular interest in oncology. The same
approaches will be applied to the entire array of protein
classes in the long term. White emphasized the need for
basic biochemical data, such as kD values, in order to
better understand and model biological processes.
“Protein Interactions”. The area of protein interactions
was discussed by many participants. Efficient approaches
and protocols now exist for mapping interactions of full-
length proteins. With quantitative proteomics, specific
binders can be distinguished from background binders.
Importantly, the specific interactions of modified pep-
tides, DNA, RNA, and small molecules with their target
proteins can now be addressed in a large-scale format.
These represent important areas of biology and biotech-
nology where few alternative techniques exist.
The effect of individual genetic differences on the
proteome (or lack thereof) has been the subject of a few
pioneering studies but is still largely unexplored [24-26].
MS-based proteomics is uniquely positioned to measure
the effects of these differences at the level where it
counts, namely the level of protein expression or activity
differences. This work will be essential to translate gen-
etic differences to differences in pathways and differ-
ences in how those pathways should be modulated by
drugs or other means.
Study design and statistical challenges in clinical
proteomics (Gilbert S. Omenn, University of Michigan,
chair)
Omenn opened this session with comments about chal-
lenges in developing omics-based tests for cancers and
other diseases. He emphasized that specification of the
intended clinical use is the critical first step. Heterogeneity
of etiology, pathogenesis, and responses to therapy among
patients with identical diagnoses and heterogeneity within
tumor masses provide major challenges for developing
tests aimed at the clinical needs of diagnosis, prognosis,
and guided therapy. Knowledge of mechanisms can en-
hance test development by providing a biological founda-
tion for the test, rather than relying on statistical
correlations. Integration of data from complementary gene
expression, genomic, epigenomic, proteomic, and metabo-
lomic platforms will enhance these complex studies.
Finally, it should be acknowledged that it is a long path of
discovery, confirmation, validation, clinical trials, and FDA
approval to establish test validity and utility and gain reim-
bursement of the laboratory service.
Several major statistical challenges were identified:
a) High-dimensional data with relatively few specimens
tested in the discovery phase inevitably lead to high risks
of over-fitting; an extreme case is two pooled specimens.
b) Multi-site collection of specimens, with pre-analytical
and analytical variation, generates prominent “lab effects”
or “batch-effects”, which can overwhelm the disease
associations; however, Nathan Price of the Institute for
Systems Biology has emphasized the value of analyzing
multiple laboratories results to estimate variance and
find a common biomarker signature. c) There are always
tradeoffs between sensitivity and specificity of test
results, corresponding to type 1 and type 2 errors (false-
positives and false-negatives); any claim of 100% sensitiv-
ity and 100% specificity should be viewed with maximal
skepticism. A better parameter for a screening test is the
positive predictive value (PPV), which takes account of
the intended clinical use and the incidence of true posi-
tives in the population to be tested. d) Bias can be intro-
duced in multiple ways (see below); for example, use of
several equivalent methods, with selective reporting of
the method that happens, perhaps randomly, to give the
most favorable results. e) The variable ways of estimating
false-positive rates in matching peptide sequences from
mass spectrometry with protein databases; PeptideAtlas
recommends a rigorous cutoff at 1% FDR (0.01) at the
protein level, which generally corresponds to 0.16%
(0.0016) at the peptide level [27].
Omenn concluded that new statistical methods and
conventions are needed to enhance the integrated ana-
lysis of omics results from multiple platforms. Even if
the data are collected from specimens on the same indi-
vidual, compounding of errors and biases is likely. Bio-
logical knowledge of meaningful, testable pathways and
networks should help in reducing biases.
Steven Skates, Massachusetts General Hospital, pre-
sented “Study Design in Omics Biomarker Research”.H e
discussed clinically-derived quantitative goals and
sources of bias that are threats to the validity of omics-
based biomarkers. It is common to characterize tests by
sensitivity (proportion of true positives detected) and
specificity (proportion of false-positives). It is necessary
to optimize the combination in light of prevalence of the
condition to be detected and clinical and ethical import-
ance of missing the diagnosis (false-negatives) or making
a false diagnosis (false-positives). A judgment about ben-
efits of true positive and true negative and harms of false
positive and false negative results is needed [28]. Perhaps
this can be done by stating a minimum benefits/harms
ratio, with input from clinicians. Skates’ example of early
Vidal et al. Clinical Proteomics 2012, 9:6 Page 6 of 11
http://www.clinicalproteomicsjournal.com/content/9/1/6detection of ovarian cancers (prevalence 1 in 2500 post-
menopausal women) showed the impact of introducing a
confirmatory test, like ultrasound, after the molecular
screening test. How many patients would have to
undergo testing and then, of those testing positive, sur-
gery to find one case of ovarian cancer? What would be
an acceptable ratio? For example, to achieve a ratio of
five surgeries to one patient with ovarian cancer would
require test specificity of 98% (2% false positives=50/
2500) plus the 10-fold benefit of ultrasound. He then
outlined the stories of OvaCheck and OvaSure as tests
that failed due to bias. The intended use for the FDA
cleared OVA1 was much narrower, “to assess the likeli-
hood of malignancy in patients with ovarian adnexal
mass when surgery is planned and not yet referred to an
oncologist”. He concluded that investigators should avoid
biased early studies, which set us off in wrong directions,
as it would be more efficient and more scientifically
sound to seek high-quality, clearly-unbiased specimens
for early stage studies.
Lisa McShane, National Cancer Institute, presented
"Statistical Issues in the Development of Reliable and
Clinically Relevant Prognostic and Predictive Proteomic
Signatures”. She discussed practical methods to
operationalize classifiers, risk scores, or decision trees as
mathematical models for molecular markers, whether
RNA, DNA, or proteins [28,29]. It is critical to define
the intended use across the categories of early detection
or risk estimation before there is a clinical diagnosis.
These categories include confirmation, staging, and sub-
typing upon diagnosis; prognosis or prediction before the
start of therapy; desired responses and potential toxicity
from therapy; and post-treatment outcomes, including
survival and absence or recurrence of disease. Predictive
signatures refer to treatment effect modifiers. Prognostic
effects are typically quantified by hazard ratio, while pre-
dictive effects are typically quantified by ratio of sub-
group-specific treatment hazard ratios. The goal is to
create and validate a clinical test from molecular data, as
has been done with the 21-gene recurrence risk score
(OncotypeDX) and the Mammaprint 70-gene signature,
which are used clinically to identify women with such
low risk of metastasis that adjunct chemotherapy can be
considered unnecessary. She demonstrated how to an-
swer such questions as: Is the prognostic information
sufficiently strong to influence clinical decisions? Does
the predictor provide information beyond standard prog-
nostic factors (i.e., “added value”)? Proper control groups
are critical for interpreting results with and without use
of the marker. Data from randomized clinical trials can
distinguish benefit of therapy only for marker-positive
participants from benefit for all participants (in which
case the marker test may not add value). The process
requires multiple steps, including lock-down of the assay
and classifier, then internal validation on suitable speci-
mens, and then external validation on independent set(s)
of specimens/data. Expert statistical steps involve feature
selection and supervised dimension/data reduction.
Over-fitting is a particularly devastating problem, which
is predictable; when there are too many parameters rela-
tive to the number of specimens or patients, the model
will describe random error or noise instead of an under-
lying relationship. Leave-one-out and other cross-valid-
ation methods also must be done expertly. Statistical
maneuvers cannot overcome built-in biases from variable
specimen handling and other lab or batch effects.
The speakers reinforced the importance of identifying
pathways and networks that make biomarker candidates
biologically meaningful and credible. There is a special
opportunity for building on NIH Common Fund pro-
grams such as the Technology Centers for Networks and
Pathways and help frame the Biology- and Disease-
driven components of the global Human Proteome Pro-
ject (B/D-HPP) being launched by the Human Proteome
Organization [3]. This would effectively leverage the tre-
mendous investments around the world that have
already been made in the mass spectrometry, protein
–capture reagents, knowledgebase pillars for the HPP,
and in the HPP chromosome-centric program.
Proteomic technologies in a clinical setting (Daniel W.
Chan, Johns Hopkins University School of Medicine, chair)
Chan discussed the translation of proteomic technologies
into a clinical setting [30-32]. He presented multiple rea-
sons for the significant gap between biomarker discovery,
validation and translation. The development of OVA1,
the first proteomic IVDMIA (in vitro diagnostic multi-
variate index assay) cleared by the FDA, was described
to illustrate the concept of “the four bridges for bio-
marker translation”: 1) clearly define a specific clinical
“intended use” (unmet clinical needs); 2) generate suffi-
cient evidence in preliminary studies to justify the invest-
ment for a large-scale validation trial; 3) select/develop
assays with performances suitable for clinical use; and 4)
conduct a pivotal clinical trial to demonstrate clinical
utility to obtain regulatory approval and to gain accept-
ance by the clinical community [31]. Chan proposed a
roadmap for the translation of proteomics technologies
into clinical settings. The roadmap requires close collab-
oration between researchers, industries, regulators, clin-
ical chemists and clinicians, including private-public
partnerships, to leverage existing NIH programs such as
the NCI Clinical Proteomics Tumor Analysis Consortia
(CPTAC) and Early Detection Research Network
(EDRN) and the NHLBI, NIDDK, and NIAD clinical
proteomic programs. Dr. Chan suggested that such a
joint effort would accelerate the development of clinic-
ally useful technologies and biomarkers and make a
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patients’ personalized health care.
Barry Dowell, Abbott Laboratories, pointed out key
challenges in biomarker commercialization: the selection
of biomarkers to address unmet needs, pre-analytical
and analytical issues, clinical performance assessment,
regulatory approval, physician education, launch of new
products, post-launch studies, and marketing issues.
These factors are all important to bring a new product
(biomarker) to market. Key considerations for a success-
ful product include clinical utility, reagent availability,
performance characteristics, patent status with freedom
to operate, and licensing terms. He emphasized pre-ana-
lytical considerations of specimen collection, biomarker
stability and its specific forms in blood, as well as bio-
logical variability. Analytical performance depends on
establishing assay design requirements, identifying key
reagent components, and optimizing test procedures and
manufacturing processes. Clinical performance requires
establishing specimen collection Standard Operating
Procedures and study designs with sufficient statistical
power. FDA submissions should use multi-site studies
with appropriate patient specimens for the specific
“intended use”. Finally, companies marketing new bio-
markers face different regulatory and re-imbursement
processes from country to country, competition from
multiple biomarkers, and the need for clinical studies to
convince the medical community of the value of the new
biomarker.
Darryl Palmer-Toy, Southern California Kaiser Perma-
nente, presented a clinical laboratory practitioner per-
spective on proteomic biomarker discovery. Taking a
biomarker from the research laboratory into the routine
clinical laboratory requires proactive three-way collabor-
ation involving the research lab, the diagnostics industry
and the clinical laboratory [29]. He stated that it’s “a jun-
gle out there” in clinical labs, and “shiny new biomarkers
quickly lose their luster”. He pointed out the importance
of properly collected patient specimens to obtain correct
analytical results and correct clinical decisions. An ideal
assay should be tough enough to stand up to abuse.
Sometimes, consistent results are more important than
“true” results (e.g. the hemoglobin A1C test for monitor-
ing diabetes). Diagnostic tests should provide clinically
useful information not available by other means and at a
reasonable cost, including quality control.
Maria M. Chan, Food and Drug Administration, gave
the FDA perspective on proteomic biomarker/technology
translation. FDA regulates In Vitro Diagnostics (IVDs)
including reagents, instruments and systems using
human specimens. FDA uses a risk-based classification
system based on the risk to the patient due to false
results: class I with low risk is exempted; class II with
medium risk requires 510(k) pre-market notification;
class III with high risk requires Pre-Marketing Approval
(PMA). “Intended Use” determines the FDA classifica-
tion, the review path and the type of study required. The
basis of device review by FDA is the balance between
safety and effectiveness. All IVDs must have adequate
analytical and clinical performances and meet labeling
requirements on, intended use, warnings, limitations, in-
terpretation of results and performance summary. For
proteomics IVDs, one should use patient specimens with
results spanning entire concentration ranges; the per-
formance at the cut-off value is critical. Precision, limit
of detection, specificity, matrix effect, accuracy, stability
and pre-analytic variables are performance criteria. Clin-
ical validation should include a study design with target
populations from a minimum of 3 sites, sample size jus-
tification, patient selection criteria and a pre-specified
hypothesis. Other pre-study considerations include ap-
propriate statistical plans, with the training set different
from the validation set; consideration of possible con-
founding co-variables; and completion of analytical valid-
ation preceding clinical validation. She recommended a
Pre-IDE as a very useful tool for a company to obtain
free protocol review by FDA and to gain advice on regu-
latory process and feedback on proposed studies. This
will prevent unnecessary waste of time and resources. Fi-
nally, she mentioned new FDA draft guidance for com-
panion diagnostics (issued 12 July 2011) and for
research-only or investigation-only (RUO and IUO) pro-
ducts (issued 1 June 2011), as well as several IVDs
cleared by the FDA for leukemia, breast, ovarian, pros-
tate and lung cancers.
Conclusions from general discussions
A session within the workshop was fully dedicated to
discuss potential scientific opportunities and identify
compelling ideas for future developments in the field of
proteomics. Several potential concepts were discussed
and considered in the context of the presentations by the
speakers. After evaluation of several important and valu-
able opportunities, the idea of generating a human prote-
ome network emerged as the most compelling
opportunity. However, it was also emphasized that, it
would be important to further support technology devel-
opment aimed at a more comprehensive characterization
of the proteome, further develop and support proteomic
data resources, and work toward an inter-agency road-
map that would facilitate the translation of proteomic
discoveries.
Human proteome networks in health and disease - A major
scientific opportunity
The Human Genome Project was initiated almost 25
years ago. Its findings and its approaches have
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genetics practice. Connecting genomics knowledge to
phenotypes is critical for common diseases; research on
functional genomics and gene/environment interactions
requires understanding and assays of proteins and protein
networks. The genome parts list has inspired a corre-
sponding approach to the identification and
characterization of protein products; rapid progress re-
cently has brought us to antibody evidence and immuno-
histochemical tissue localization of ~12,000 of the
~20,000 predicted protein gene products in the Human
Protein Atlas and mass spectrometry-based evidence in
SwissProt/UniProt for about 13,000 of the ~20,000 pro-
tein products. Completion of the protein parts list is
the primary goal of The Human Proteome Project,
using both chromosome-centric and biology/disease-
driven approaches [3]. That leaves enormous work to
be done on protein isoforms, dynamic regulation of
protein expression, and interactions of proteins with
macromolecules and small molecules critical to cellular
and organismal function.
Projecting ahead 25 years, the participants of this
Workshop envision that one of the most promising out-
comes of this modern biomedical research, and especially
a focus on protein networks, could be the transformation
of health care into a predictive, preventive, personalized
and participatory system of care (“P4 medicine”) [33].
Key pillars of P4 medicine are emerging from omics-
based research and the field of systems biology. Inter-
pretation of complete personal genome sequence data
will require a much better knowledge of how gene pro-
ducts encoded by the human genome interact with each
other to contribute to complex molecular interactome
networks and cellular systems that underlie the biology
of our tissues and organs. Extensive understanding of the
functional, dynamic and logical relationships taking place
in the context of complex interactome networks will
eventually drive two major aspects of P4 medicine: inte-
grated biomarker discovery and systems pharmacology.
Biomarker discovery will improve the predictability of
specific diseases by integrating personal genomics infor-
mation, knowledge of environmental components and
understanding of the properties of cellular systems. Simi-
larly, safer and more predictably effective personalized
therapies will emerge from understanding of complex
relationships between proteins and cellular networks.
What became increasingly clear throughout this Work-
shop is that one critical component missing for this vi-
sion to eventually become reality is a freely-available
global map of the human proteome in terms of macro-
molecular interactions between its components, i.e. a wir-
ing diagram of functional relationships between genes and
gene products. We see the development of a Human Pro-
tein Network as a major scientific opportunity. A nearly
complete map of human protein-protein, protein-nucleic
acid, and protein-small molecule interactions could be
generated and this information could be combined with
biologically-driven findings to complete the human prote-
ome parts list and functional networks for the ~20,000
protein-coding genes and their products. Comparative
analyses in model organisms would enhance the human
studies. One of the major outcomes of such interactome
maps would be a wiring diagram that could be used to
make sense of complex traits starting from currently avail-
able Genome-Wide Association studies (GWAS), at least
those variants producing non-synonymous mutations in
protein-coding genes, cancer genome sequencing efforts
such as The Cancer Genome Atlas (TCGA), and key con-
sortia such as ENCODE. Interactome network maps
would serve as foundational information for systems biol-
ogy, enhance understanding of the pathways between gen-
otypes and phenotypes, and improve the predictive power
of integrated and personalized biomarkers, therapies, and
combinations of therapies.
Models exist as to how one could organize a global
large-scale study, inspired by the Human Genome Pro-
ject and its many follow-on initiatives. In terms of the
specific needs to address the dynamic aspects of prote-
ome function, rather than the linear and binary informa-
tion in DNA sequences, we find inspiration in the
example of the ENCODE consortium. ENCODE uses
defined cell lines to generate high-throughput unbiased
systematic datasets and maps of protein-DNA interac-
tions, but leaves biological studies and functional follow-
ups to other granting mechanisms.
A Network Biology/Interactome Mapping Project can
be defined in terms of end-point goals and intermediate
milestones using empirical frameworks. For a compre-
hensive human binary protein-protein interactome net-
work, it has been established that on the order of
~150,000 interactions are to be found in what will con-
stitute the “Reference” interactome network [34]. At this
stage, the combination of low-throughput and high-
throughput datasets curated by databases such as Bio-
Grid (see above) indicate that the community has
assembled about 20% of that number of high quality
interactions of the Reference interactome network. In
other words approximately 80% of the interactome
remains to be mapped.
Static maps of macromolecular interactions need to be
combined with network-based datasets consisting of
other types of functional and dynamic relationships be-
tween genes and gene products, such as: i) protein ex-
pression data by measuring precisely the proteome
content of particular cell lines and tissues, as demon-
strated elegantly by Mann during the Workshop, ii) tissue
and subcellular localization data obtained using both
mass spectrometry and immunohistochemistry, iii)
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get relationships as measured by protein arrays, and then
iv) translation of the corresponding gene-gene network
information into a better description of tissue lysates and
body fluids for integrated biomarker discovery efforts.
In terms of future directions, it will be crucial to
organize this map such that it can be used to generate
dynamic models that can be integrated with both Men-
delian and complex multifactorial diseases. It will be ex-
tremely important to democratize access to peptide and
protein data, interactome networks data, and powerful
analytical platforms. The Workshop participants agreed
that it is feasible to generate a human macromolecular
interaction map with the technology that is available
today. However, developing new technology platforms
for proteomic analysis is needed to better characterize
the heterogeneity of tissues and tumors.
In summary, a major obstacle to being able to move
forward with integrated biomarker discovery and systems
pharmacology is the generation of a high quality, freely
available and nearly complete map of the human interac-
tome network. This rapidly emerging scientific challenge
is also a great scientific opportunity. Such a project
would benefit from and go beyond the example of the
ENCODE consortium, particularly in terms of shared
goals by the participants and shared quality standards to
map the interactome network. A protein interactome
networks effort would build on previous and current
trans-NIH Common Fund investments, including the
National Centers for Biocomputing, the Technology
Centers for Networks and Pathways, the Library of Inte-
grated Network-based Cellular Signatures, the Protein
Capture Reagents, and the Interdisciplinary Research
Consortia. If implemented to a sufficiently large extent
this interactome mapping project could have a high im-
pact by producing a systematic, unbiased, freely available
wiring diagram for a systems biology-based implementa-
tion of P4 medicine.
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